OverviewSuggest Edit

Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.

TypePublic
Founded1997
HQSalt Lake City, UT, US
Websitelipocine.com

Latest Updates

Employees (est.) (Dec 2019)12(+20%)
Revenue (FY, 2020)$0(-100%)
Share Price (Jul 2021)$1.3
Cybersecurity ratingAMore

Key People/Management at Lipocine

Mahesh V. Patel

Mahesh V. Patel

Chairman, President and Chief Executive Officer
Morgan Brown

Morgan Brown

Executive Vice President and Chief Financial Officer
Anthony DelConte

Anthony DelConte

Chief Medical Director
Show more

Lipocine Office Locations

Lipocine has offices in Salt Lake City and Trenton
Salt Lake City, UT, US (HQ)
675 Arapeen Dr #202
Trenton, NJ, US
3150 Brunswick Pike #130
Show all (2)

Lipocine Financials and Metrics

Lipocine Revenue

USD

Net income (FY, 2020)

(21.0m)

EBIT (FY, 2020)

(18.0m)

Market capitalization (16-Jul-2021)

111.2m

Closing stock price (16-Jul-2021)

1.3

Cash (31-Dec-2020)

19.2m

EV

102.6m
Lipocine's current market capitalization is $111.2 m.
Annual
USDFY, 2012FY, 2013Y, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

428.0k165.0k

General and administrative expense

76.7k3.6m5.0m5.8m10.4m10.2m5.3m5.6m8.2m

R&D expense

5.1m15.5m12.6m8.1m11.0m6.5m7.5m9.7m

Operating expense total

76.7k8.8m20.6m18.6m19.2m21.2m11.8m13.1m18.0m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

428.0k165.0k

General and administrative expense

2.2k3.3k5.7k3.2k6.3k1.2m1.9m1.0m871.8k1.1m1.1m1.7m4.4m3.2m1.4m1.8m2.0m2.7m1.7m1.7m930.1k1.2m1.4m1.4m2.1m2.0m

R&D expense

1.6m3.4m6.0m3.2m1.9m3.2m4.7m2.7m2.6m1.5m3.1m4.1m2.0m1.4m1.5m1.4m1.9m2.0m1.7m2.5m2.3m

Operating expense total

2.2k3.3k5.7k3.2k6.3k2.8m5.3m7.0m4.1m3.0m4.3m6.5m7.1m5.9m3.3m5.0m6.2m4.8m3.1m3.2m2.4m3.1m3.4m3.1m4.6m4.2m
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

577.045.3m27.7m20.0m5.6m3.2m8.1m9.7m19.2m

Accounts Receivable

Prepaid Expenses

770.0k229.9k350.2k408.2k520.1k545.9k661.3k

Inventories

Show all financial metrics

Lipocine Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Lipocine Online and Social Media Presence

Embed Graph

Lipocine News and Updates

Thinking about buying stock in Verb Technology, Casper Sleep, Millendo Therapeutics, Lipocine, or Hepion Pharmaceuticals?

NEW YORK, July 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VERB, CSPR, TPST, LPCN, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Clarus Therapeutics Announces Comprehensive Settlement of Patent Litigation With Lipocine

Clarus Therapeutics Inc. ("Clarus") and Lipocine, Inc. (“Lipocine”) agree to resolve all outstanding claims between the companies in the on-going intellectual property litigation (U. S. District Court for the District of Delaware) and patent interference (U. S. Patent & Trademark Office; USPTO) …

Lipocine To Present At The Raymond James Human Health Innovation Conference

SALT LAKE CITY, June 16, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Company will present at the Raymond James Human Health Innovation Conference. The conference will...

Thinking about buying stock in Mereo BioPharma, Lipocine, Lordstown Motors, Sorrento Therapeutics, or Axcella Health?

NEW YORK, June 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MREO, LPCN, RIDE, SRNE, and AXLA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2021

SALT LAKE CITY, May 6, 2021 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. First Quarter...

Lipocine Announces Tentative Approval of TLANDO™

SALT LAKE CITY, Dec. 8, 2020 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted tentative approval to TLANDO, its oral...
Show more

Lipocine Frequently Asked Questions

  • When was Lipocine founded?

    Lipocine was founded in 1997.

  • Who are Lipocine key executives?

    Lipocine's key executives are Mahesh V. Patel, Morgan Brown and Anthony DelConte.

  • How many employees does Lipocine have?

    Lipocine has 12 employees.

  • Who are Lipocine competitors?

    Competitors of Lipocine include PhagePro, Akthelia and Bioiberica.

  • Where is Lipocine headquarters?

    Lipocine headquarters is located at 675 Arapeen Dr #202, Salt Lake City.

  • Where are Lipocine offices?

    Lipocine has offices in Salt Lake City and Trenton.

  • How many offices does Lipocine have?

    Lipocine has 2 offices.